Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:18 PM
Ignite Modification Date:
2025-12-24 @ 5:18 PM
NCT ID:
NCT00006250
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically proven newly diagnosed stage III or IV follicular non-Hodgkin's lymphoma
* REAL classification grade I, II, or III
* Treatment necessity indicated by presence of the following:
* B symptoms
* Bone marrow failure
* Bulky or progressive disease
* Compression syndromes
* No CNS involvement
PATIENT CHARACTERISTICS:
Age:
* 18 to 70
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* No autoimmune hemolytic anemia or active hemolysis
* Direct Coombs' negative
Hepatic:
* Alkaline phosphatase no greater than 2.5 times upper limit of normal (ULN)\*
* Bilirubin no greater than 2.5 times ULN\* NOTE: \*Unless attributable to lymphoma
Renal:
* Creatinine no greater than 2.5 times ULN (unless attributable to lymphoma)
Cardiovascular:
* No severe cardiac failure
* Ejection fraction at least 45%
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for at least 6 months after study
* HIV negative
* No prior malignancy except carcinoma in situ of the cervix or squamous cell skin cancer
* No other serious medical disease that would limit lifespan or ability to tolerate chemotherapy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* No concurrent systemic corticosteroids
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No prior therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT00006250
Study Brief:
Protocol Section:
NCT00006250